HLB Pep Co., Ltd. (KOSDAQ:196300)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,340.00
+450.00 (6.53%)
At close: Apr 1, 2026
Market Cap68.21B +69.1%
Revenue (ttm)4.96B -20.3%
Net Income-642.47M
EPS-75.00
Shares Out9.29M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,034
Average Volume19,461
Open7,000.00
Previous Close6,890.00
Day's Range6,900.00 - 7,340.00
52-Week Range6,210.00 - 10,850.00
Beta0.23
RSI51.46
Earnings Daten/a

About HLB Pep

HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 196300
Full Company Profile

Financial Performance

In 2025, HLB Pep's revenue was 4.96 billion, a decrease of -20.34% compared to the previous year's 6.23 billion. Losses were -642.47 million, -90.54% less than in 2024.

Financial Statements